Particularly against severe / pandemic-risk disease such as CoV-2, H5N1, or so on.
Resolves YES if one is published which shows statistically significant effects using mushroom or mycelium-derived extracts or compounds. Otherwise NO at end of 2026.
1,000Does Shao et al., Phytochemistry 247 (2026), satisfy the published criterion? It studied Ganoderma lucidum-derived triterpenes in influenza A cell assays and reports significant reductions in virus-induced IL-1β or IL-6. PubMed lists online publication on March 25, 2026: https://pubmed.ncbi.nlm.nih.gov/41895425/ (DOI: 10.1016/j.phytochem.2026.114877).
This is in-vitro evidence, not demonstrated patient benefit. The description includes mushroom-derived compounds and does not specify a human trial, so it looks like a possible YES under that broad wording.